Profiles of Leading Women Scientists on AcademiaNet.
Search among the members of the Leopoldina for experts in specific fields or research topics.
Image: Markus Scholz | Leopoldina
Year of election: | 2017 |
Section: | Human Genetics and Molecular Medicine |
City: | Waltham, MA |
Country: | USA |
Research Priorities: Protein dynamics in atomic resolution, evolution of enzyme catalysis, allostery and biological regulation, protein dynamics-based development of medicines
Dorothee Kern is a biochemist and works on the dynamic nature of proteins. She substantially contributed to the experimental characterization of protein dynamics both during the catalysis of enzymes and during signal transmission. The goal of her research is to further unveil the complex interplay between structure, dynamics, and function to develop new medicines.
The research group of Dorothee Kern employs biophysical techniques of analysis to investigate the dynamics of enzymes as well as the signalling proteins and molecules which influence them. Here, the focus lies especially on the catalysis of enzymes, the evolution of complex signalling functions and the fundamental biophysical principles for developing highly selective drugs.
Many of the biological processes in higher organisms are shaped by a myriad of proteins and molecules that have a signalling function. Here, change over time is a key feature of life. The team around Dorothee Kern investigates the changes of the proteins’ atomic architectures on a molecular scale. For this purpose, they employ methods such as NMR (nuclear magnetic resonance spectroscopy), x-ray crystallography, single-molecule FRET (Fluorescence-Resonance-Energy-Transfer), EM, simulations of molecular dynamics, bioinformatics, and AI. These techniques provide real-time visibility of the proteins’ functioning in atomic resolution: enzymes during catalysis, signalling proteins in action, and proteins or medicines connecting to target molecules. With this advancement in knowledge the team hopes to develop novel medicines such as specific inhibitors, and to develop novel green biocatalysts in form of evolved enzymes.